DB:AJW

Stock Analysis Report

Executive Summary

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products.

Snowflake

Flawless balance sheet with poor track record.

Share Price & News

How has AnGes's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AJW's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.2%

AJW

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

75.3%

AJW

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: AJW exceeded the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: AJW exceeded the German Market which returned 10.9% over the past year.


Shareholder returns

AJWIndustryMarket
7 Day5.2%5.5%-0.3%
30 Day14.0%-0.8%2.6%
90 Day-16.0%-4.8%11.8%
1 Year75.3%75.3%-1.6%-1.9%14.4%10.9%
3 Year192.3%192.3%65.5%63.4%24.1%13.2%
5 Year150.8%150.8%7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is AnGes's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AnGes undervalued compared to its fair value and its price relative to the market?

6.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AJW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AJW's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AJW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AJW is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AJW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AJW is overvalued based on its PB Ratio (6.1x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is AnGes forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

50.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AnGes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AnGes performed over the past 5 years?

-0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AJW has high quality earnings.

Growing Profit Margin: AJW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AJW is unprofitable, and losses have increased over the past 5 years at a rate of -0.4% per year.

Accelerating Growth: Unable to compare AJW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AJW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: AJW has a negative Return on Equity (-27.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AnGes's financial position?


Financial Position Analysis

Short Term Liabilities: AJW's short term assets (¥11.9B) exceeds its short term liabilities (¥341.0M)

Long Term Liabilities: AJW's short term assets (¥11.9B) exceeds its long term liabilities (27.0M)


Debt to Equity History and Analysis

Debt Level: AJW is debt free.

Reducing Debt: AJW has not had any debt for past 5 years.


Balance Sheet

Inventory Level: AJW has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AJW's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AJW has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AJW has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.5% each year


Next Steps

Dividend

What is AnGes's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AJW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AJW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AJW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AJW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AJW's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of AnGes's salary, the management and board of directors tenure and is there insider trading?

6.1yrs

Average board tenure


CEO

Ei Yamada (69yo)

17.2yrs

Tenure

0

Mr. Ei Yamada, Ph.D. has been the President and Chief Executive Officer of AnGes MG Inc since September 2002. Mr. Yamada has been the Chief Executive Officer at AnGes Euro Limited since June 2002 and AnGes ...


Board Age and Tenure

6.1yrs

Average Tenure

71yo

Average Age

Experienced Board: AJW's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.


Management Team

  • Ei Yamada (69yo)

    President

    • Tenure: 17.2yrs

Board Members

  • Ei Yamada (69yo)

    President

    • Tenure: 17.2yrs
  • Tadashi Hishida (85yo)

    Corporate Auditor

    • Tenure: 17.4yrs
  • Makoto Hara

    Director

    • Tenure: 1.7yrs
  • Akihiro Narimatsu (72yo)

    Corporate Auditor

    • Tenure: 6.7yrs
  • Junichi Komamura (69yo)

    Director

    • Tenure: 7.7yrs
  • Norikazu Eiki (71yo)

    Director

    • Tenure: 5.5yrs
  • Seiji Hirasaki

    Director

    • Tenure: 2.7yrs
  • Katsunori Horikoshi

    Standing Corporate Auditor

    • Tenure: 2.7yrs

Company Information

AnGes, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AnGes, Inc.
  • Ticker: AJW
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥78.837b
  • Listing Market Cap: JP¥656.136m
  • Shares outstanding: 106.97m
  • Website: https://www.anges.co.jp

Number of Employees


Location

  • AnGes, Inc.
  • Saito Bio-Incubator
  • 1st Floor
  • Ibaraki
  • Osaka
  • 567-0085
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4563TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYSep 2002
AJWDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2002

Biography

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatmen ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 20:59
End of Day Share Price2019/11/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.